About this trial
The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisting of calming natural scenes, guided meditation, and music. The study population includes adult surgical ICU patients at Cedars-Sinai who are CAM-ICU negative at enrollment and possess at least one established risk factor for delirium. Outcomes will include the incidence and duration of delirium, ICU and hospital length of stay, feasibility of the VR intervention, and the frequency of adverse events. By targeting a high-risk population with an innovative non-pharmacologic therapy, this trial aims to generate data to support integration of VR into ICU delirium prevention protocols.
Eligibility criteria
Qualifiers
Individuals who are currently admitted to the SICU at Cedars-Sinai Medical Center
Expected ICU stay >48 hours
Richmond Agitation Sedation Scale (RASS) score between -1 to +2.
CAM-ICU negative
Disqualifiers
Unwilling and/or unable to participate
Intubation of tracheostomy
Self-reported history of severe motion sickness
Inability to follow commands (e.g. severe aphasia, deafness, GCS<13)
Trial design
Treatments tested in this trial
- Virtual Reality therapeutics